Traduction de «stroke » (Français → Néerlandais) :

Remerciements : Pour son aide précieuse relative à la méta-analyse : Cécile Dubois (KCE) Pour leur contribution au scoring des indicateurs : Raf Brouns et Matthieu Rutgers (Belgian Stroke Council) Pour la validation de la description de leur pays : Suède : Kiell Asplund (Chair, Risks Stroke Umea), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Pays-Bas : Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk) Ecosse : Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Grande-Bretagne : Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) France : France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ilede-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Allemagne : Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)
Acknowledgements: Voor haar waardevolle bijdrage in het gedeelte over meta-analyse: Cécile Dubois (KCE) Voor hun bijdrage bij het scoren van de indicatoren: Raf Brouns en Matthieu Rutgers (Belgian Stroke Council) Voor het valideren van de informatie over hun land: Zweden: Kiell Asplund (Chair, Risks Stroke Umeal), Bo Norrving (Professor, Lund University-Steering committee member Riks stroke) Nederland: Martien Limburg (Neuroloog, Flevoziekenhuis, Almere, Stichting Kennisnetwerk); Schotland: Martin Dennis (Division of Clinical Neurosciences – Western General Hospital University of Edinburgh), Peter Langhorne (Professor of Stroke Care, Cardiovascular and Medical Sciences Division – University of Glasgow) Verenigd Koninkrijk: Patrick Gompertz (Barts and the London Brain Attack Center, London), Gill Gluckie (Clinical lead, stroke, Guy’s and St. Thomas’ hospital, clinical lead, S/East London stroke network) Frankrijk: France Woimant (Service de neurologie, hôpital Lariboisière, Paris – “Agence Régionale de Santé – Ile-de-France”), Didier Leys (Département de neurologie, Hôpital universitaire de Lille) Duitsland: Peter Heuschmann (Neurologische klinik und poliklinik, Universitätsklinikum Würzburg) German Stroke Register Study Group), E. Bernd Ringelstein (Neurologische klinik und poliklinik, Universitätsklinikum Münster)

Furie KL, Kasner SE, Adams RJ et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.
professionals from the American Heart Association/American Stroke Association.

7, 8 Figure 2 shows the danger of combined risk factors, as these tend to interact: all three for stroke important risk factors give you the stroke risk of a person that is not less than 32 years older.
1A).7, 8 shows the danger of combined risk factors, as these tend to interact: all three for stroke important risk factors give you the stroke risk of a person that is not less than 32 years older.

randomized trials.1 Effective strategies for the secondary prevention of stroke include treatment of hypertension and hyperlipidemia, antithrombotic therapy for patients with atrial fibrillation, and antiplatelet therapy (Evidence level 1). 1 Statins are effective in the prevention of stroke, although evidence remains limited to heart disease patients (Evidence level 1). 2, 3
treatment of hypertension and hyperlipidemia, antithrombotic therapy for patients with atrial fibrillation, and antiplatelet therapy (Evidence level 1).1 Statins are effective in the prevention of stroke, although evidence remains limited to heart disease patients (Evidence level 1).2, 3

C’est pour répondre à cette nécessité que sont apparues les “unités neuro-vasculaires” (Stroke Units, du mot anglais stroke qui désigne l’AVC) qui permettent notamment de mettre en œuvre immédiatement les techniques de diagnostic et les traitements de thrombolyse, ainsi que d’autres améliorations spécifiques des soins, de façon à diminuer la mortalité et à améliorer les chances de récupération.
Om aan deze noodzaak te voldoen zijn de " Neuro-vasculaire Eenheden" (Stroke units, van het Engelse woord stroke, dat CVA betekent) ontstaan, die het mogelijk maken om onmiddellijk technische diagnostische onderzoeken en een behandeling met trombolyse uit te voeren, en die ook andere specifieke verbeteringen mogelijk maken wat betreft zorg, om zo de mortaliteit te doen dalen en de kans op herstel te vergroten.

Search Date February 2009. [http ...]
Aguilar MI, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.

Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: anti-thrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Des unités neurovasculaires (stroke units’ ) existent depuis quelques années dans certains hôpitaux belges.
Sinds enkele jaren bestaan er in een aantal Belgische ziekenhuizen ‘stroke units’.

Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke.
Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke [see comments].

For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several
For primary prevention of stroke, adequate blood pressure reduction, and treatment of hyperlipidemia, use of antithrombotic therapy in patients with atrial fibrillation and of antiplatelet therapy in patients with myocardial infarction are effective and supported by evidence from several randomized trials.1 Effective strategies for the secondary prevention of stroke include